URI Researcher Awarded $13M for Development of Vaccines for Emerging Infectious Diseases
Published on August 20, 2009
University of Rhode Island Professor Annie De Groot has been awarded a $13 million grant from the National Institutes of Health (NIH) to initiate the development and application of an integrated gene-to-vaccine program targeting emerging infectious diseases. De Groot, who just recently joined the URI faculty, has now brought in over $25 million in research funds to the state.
The NIH funds will enable De Groot and URI colleagues Thomas Mather and Lenny Moise to collaborate with Lifespan's Steve Moss and Steve Gregory, as well as Bill Martin of EpiVax, to develop vaccines that will address emerging infectious diseases and move those vaccine products towards the clinic.
The funding will also support a training course and pilot grants for researchers interested in using new vaccine design tools developed by De Groot and Martin. The first training session will take place on August 24-26 at the URI Providence Biotechnology Center.